H.C. Wainwright Initiates Coverage On Aridis Pharmaceuticals with Buy Rating, Announces $7 Price Target

H.C. Wainwright analyst Vernon Bernardino initiates coverage on Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy rating and a $7 price target.

Benzinga · 12/30/2019 12:05

H.C. Wainwright analyst Vernon Bernardino initiates coverage on Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy rating and a $7 price target.